MedDay Raises €34m For US Trial As EU Filing Of MS Drug Nears

MedDay of France, which is preparing a European filing for its progressive multiple sclerosis product MD1003, has raised €34m in a Series B financing round. Edmond de Rothschild Investment Partners (EDRIP) led the new investment round alongside existing investors Sofinnova Partners, the company's largest shareholder, and InnoBio (Bpifrance). Large Venture (Bpifrance) also participated.